You are here: Industry Insights > melanoma

News List

NICE clears Pierre Fabre's targeted melanoma combo to take on Novartis, Roche drugs fiercepharma
January 22, 2019
Thanks to new guidance from England’s drug cost watchdog, Novartis and Roche will be getting some fresh targeted melanoma competition from French pharma lab Pierre Fabre.
NICE clears Pierre Fabre's targeted melanoma combo to take on Novartis, Roche drugs fiercepharma
January 22, 2019
Thanks to new guidance from England’s drug cost watchdog, Novartis and Roche will be getting some fresh targeted melanoma competition from French pharma lab Pierre Fabre.
AIVITA Biomedical Receives IND Clearance for Phase 1B Melanoma Trial americanpharmaceuticalreview
January 17, 2019
AIVITA Biomedical announced the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for a Phase 1B clinical trial investigating the Company's ROOT OF CANCER technology in .....
Cancer-killing virus plus PD-1 and MEK inhibitors make for a 3-pronged attack on melanoma fiercebiotech
December 26, 2018
When Amgen’s cancer-killing virus Imlygic—also known as T-Vec—was approved by the FDA in late 2015, experts expected it would work best in combination strategies for melanoma.....
Idera’s TLR9-Yervoy combo sees ‘impressive’ disease control in PD-1-refractory melanoma fiercebiotech
December 26, 2018
After reporting positive phase 1 results suggesting its TLR9 agonist tilsotolimod could work in synergy with CTLA4 inhibitor Yervoy in melanoma patients who progress on anti-PD-1....
Merck bags adjuvant okay for Keytruda in melanoma pharmaphorum
December 19, 2018
Checkpoint inhibitors have already revolutionised the treatment of advanced melanoma, and Merck & Co has just claimed approval for even earlier use of its Keytruda product in Europe.
BMS flips negative NICE ruling on Opdivo, winning thumbs-up for preventing melanoma relapse fiercepharma
December 04, 2018
In September, Britain’s drug-cost watchdog, The National Institute for Health and Care Excellence (NICE), said Bristol-Myers Squibb did not make a convincing enough case that PD-1
NICE backs use of Bristol-Myers Squibb's Opdivo via Cancer Drugs Fund for completely resected melanoma firstwordpharma
December 02, 2018
The National Institute for Health and Care Excellence issued a final appraisal document on Friday recommending use of Bristol-Myers Squibb's Opdivo (nivolumab) within the Cancer Drugs Fund (CDF) as an option for the adjuvant treatment of completely resect
NICE u-turn on Opdivo for skin cancer recurrence pharmatimes
November 30, 2018
NHS use of Bristol-Myers Squibb’s Opdivo to cut the risk of early stage skin cancer recurrence after surgery has now been approved by the National Institute for Health and Care Excellence...
NICE rejects Opdivo for preventing melanoma recurrence pharmatimes
November 27, 2018
NHS funding for use of Bristol-Myers Squibb’s Opdivo as an adjuvant treatment for resected stage III and IV melanoma is being blocked by the National Institute for Health and Care Excellence.

Previous page 1 2 3 4 5 6 7 Next page